Contact
Please use this form to send email to PR contact of this press release:
Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer
TO: